Stichting Hemato-Oncologie voor Volwassenen Nederland

4 in Phase 3

Quick facts

Phase 3 pipeline

Daunorubicin or Idarubicin · Oncology
Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA damage and cancer cell death.
Placebo for AG-120 · Oncology
This drug is a placebo, meaning it has no active therapeutic effect.
Placebo for AG-221 · Oncology
This is a placebo control with no active pharmacological mechanism.
Venetoclax 400 · Oncology
Venetoclax is a small molecule inhibitor of the BCL-2 protein, which is involved in apoptosis regulation.

Phase 2 pipeline

DA-EPOCH-R followed by Nivolumab · Oncology
DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, followed by Nivolumab, a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.
gemcitabine, cisplatin and tislelizumab
ibrutinib, venetoclax
ibrutinib, venetoclax, obinutuzumab
Zanubrutinib Oral Capsule

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Stichting Hemato-Oncologie voor Volwassenen Nederland

What is Stichting Hemato-Oncologie voor Volwassenen Nederland's pipeline?

Stichting Hemato-Oncologie voor Volwassenen Nederland has 4 drugs in Phase 3, 5 in Phase 2, 0 in Phase 1. Late-stage candidates include Daunorubicin or Idarubicin, Placebo for AG-120, Placebo for AG-221, Venetoclax 400.

Sector hub: All tracked pharma companies